The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | New therapies shaping the future of amyloidosis
Giampaolo Merlini, MD from Scientific Institute Policlinico San Matteo, University of Pavia, Pavia, highlights the new types of therapeutic agents available for amyloidosis patients. Prof. Merlini provides details on a new oral proteasome inhibitor Ixazomib which has shown to be well tolerated with excellent response rate. Secondly he provides an overview on current immunotherapies specifically daratumumab, and also antibodies targeting amyloidosis deposits particularly protein serum amyloid P component (SAP) which has shown encouraging results. Recorded at the European Hematological Association (EHA) 2017 in Madrid, Spain.
